Rank

Article

Citations

Citation rate

1

The Banff 97 working classification of renal allograft pathology. Kidney International. 1999; 55: 713-23.

2418

115.1

2

Improved graft survival after renal transplantation in the United States, 1988 to 1996. New England Journal of Medicine. 2000; 342: 605-12.

1402

70.1

3

Banff 07 classification of renal allograft pathology: Updates and future directions. American Journal of Transplantation. 2008; 8: 753-60.

1396

116.3

4

International standardization of criteria for the histologic diagnosis of renal-allograft rejection – The banff working classification of kidney-transplant pathology. Kidney International. 1993; 44: 411-22.

1167

43.2

5

KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation. 2009; 9: S1-S155.

1125

102.3

6

Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal-allograft recipients. Transplantation. 1995; 60: 225-32.

1121

44.8

7

Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine. 2007; 357: 2562-75.

1094

84.2

8

High survival rates of kidney-transplants from spousal and living unrelated donors. New England Journal of Medicine. 1995; 333: 333-6.

880

35.2

9

Immunosuppressive drugs for kidney transplantation. New England Journal of Medicine. 2004; 351: 2715-29.

878

54.9

10

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997; 63: 977-83.

875

38

11

Diabetes mellitus after kidney transplantation in the United States. American Journal of Transplantation. 2003; 3: 178-85.

868

51.1

12

A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996; 61: 1029-37.

841

35

13

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of Transplantation. 2004; 4: 378-83.

834

52.1

14

Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. New England Journal of Medicine. 2002; 347: 488-96.

789

43.8

15

Antibody-mediated rejection criteria – an addition to the Banff ’97 Classification of Renal Allograft Rejection. American Journal of Transplantation. 2003; 3: 708-14.

782

46

16

CTLA4-Ig and anti-CD4O ligand prevent renal allograft rejection in primates. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 8789-94.

755

32.8

17

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet. 2000; 356: 194-202.

733

36.7

18

A study of the quality of life and cost-utility of renal transplantation. Kidney International. 1996; 50: 235-42.

716

29.8

19

Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation. 1997; 63: 968-74.

706

30.7

20

Brief report: HLA-mismatched renal transplantation without maintenance immunosuppression. New England Journal of Medicine. 2008; 358: 353-61.

704

58.7

21

Sirolimus (rapamycin)-based therapy in human renal transplantation – Similar efficacy and different toxicity compared with cyclosporine. Transplantation. 1999; 67: 1036-42.

703

33.5

22

Cancer after kidney transplantation in the United States. American Journal of Transplantation. 2004; 4: 905-13.

690

43.1

23

Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. American Journal of Transplantation. 2012; 12: 388-99.

677

84.6

24

Cancer incidence before and after kidney transplantation. Jama-Journal of the American Medical Association. 2006; 296: 2823-31.

660

47.1

25

Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation. 2005; 79: 1277-86.

655

43.7

26

Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:

652

27.2

27

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New England Journal of Medicine. 1998; 338: 161-5.

648

29.5

28

Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. New England Journal of Medicine. 2005; 352: 1317-23.

640

42.7

29

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Medicine. 1999; 5: 686-93.

639

30.4

30

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361: 2024-31.

625

36.8

31

Costimulation blockade with belatacept in renal transplantation. New England Journal of Medicine. 2005; 353: 770-81.

623

41.5

32

Medical progress – Strategies to improve long-term outcomes after renal transplantation. New England Journal of Medicine. 2002; 346: 580-90.

620

34.4

33

Delayed graft function in kidney transplantation. Lancet. 2004; 364: 1814-27.

613

38.3

34

Risk-factors for chronic rejection in renal-allograft recipients. Transplantation. 1993; 55: 752-7.

613

22.7

35

Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. Journal of the American Society of Nephrology. 2001; 12: 589-97.

563

29.6

36

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection – A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 1997; 64: 436-43.

558

24.3

37

Machine perfusion or cold storage in deceased-donor kidney transplantation. New England Journal of Medicine. 2009; 360: 7-19.

554

50.4

38

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997; 350: 1193-8.

539

23.4

39

Comparison of survival probabilities for dialysis patients vs cadaveric renal- transplant recipients. Jama-Journal of the American Medical Association. 1993; 270: 1339-43.

533

19.7

40

Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology. 1996; 7: 158-65.

532

22.2

41

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). American Journal of Transplantation. 2010; 10: 547-57.

529

52.9

42

Long-term survival in renal transplant recipients with graft function. Kidney International. 2000; 57: 307-13.

528

26.4

43

Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney International. 2002; 62: 311-8.

525

29.2

44

Rapid loss of vertebral mineral density after renal-transplantation. New England Journal of Medicine. 1991; 325: 544-50.

523

18

45

Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. New England Journal of Medicine. 2003; 349: 125-38.

522

30.7

46

Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant. American Journal of Transplantation. 2012; 12: 1157-67.

510

63.8

47

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351: 623-8.

504

22.9

48

Long-term renal allograft survival in the United States: A critical reappraisal. American Journal of Transplantation. 2011; 11: 450-62.

501

55.7

49

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New England Journal of Medicine. 1999; 340: 1462-70.

495

23.6

50

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. New England Journal of Medicine. 2005; 352: 558-69.

493

32.9

51

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. New England Journal of Medicine. 1987; 317: 1049-54.

488

14.8

52

Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation. 2002; 74: 1281-6.

487

27.1

53

Mycophenolate mofetil in renal allograft recipients – A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation. 1997; 63: 39-47.

482

21

54

Identifying Specific Causes of Kidney Allograft Loss. American Journal of Transplantation. 2009; 9: 527-35.

476

43.3

55

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. Journal of the American Society of Nephrology. 2010; 21: 1398-406.

475

47.5

56

Incidence of skin-cancer after renal-transplantatin in the Netherlands. Transplantation. 1990; 49: 506-9.

475

15.8

57

A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalo-virus disease in recipients of renal-allografts. New England Journal of Medicine. 1989; 320: 1381-7.

475

15.3

58

Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. New England Journal of Medicine. 2013; 369: 1215-26.

472

67.4

59

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001; 71: 271-80.

471

24.8

60

The effect of patients’ preferences on racial differences in access to renal transplantation. New England Journal of Medicine. 1999; 341: 1661-9.

458

21.8

61

Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? American Journal of Transplantation. 2004; 4: 1289-95.

456

28.5

62

Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes – A paired donor kidney analysis. Transplantation. 2002; 74: 1377-81.

454

25.2

63

Cancer risk after renal-transplantation in the nordic countries, 1964-1986. International Journal of Cancer. 1995; 60: 183-9.

452

18.1

64

Rituximab and intravenous immune globulin for desensitization during renal transplantation. New England Journal of Medicine. 2008; 359: 242-51.

451

37.6

65

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000; 70: 887-95.

449

22.5

66

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000; 69: 1252-60.

447

22.4

67

Association of chronic kidney graft failure with recipient blood pressure. Kidney International. 1998; 53: 217-22.

447

20.3

68

Influence of cyclosporin pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney-transplantation. Clinical Pharmacology & Therapeutics. 1993; 54: 205-18.

445

16.5

69

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. American Journal of Transplantation. 2009; 9: 2520-31.

443

40.3

70

Identification of a B cell signature associated with renal transplant tolerance in humans. Journal of Clinical Investigation. 2010; 120: 1836-47.

441

44.1

71

Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation. 1995; 59: 256-62.

436

17.4

72

Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. New England Journal of Medicine. 2001; 344: 947-54.

429

22.6

73

Recommendations for the outpatient surveillance of renal transplant recipients. Journal of the American Society of Nephrology. 2000; 11: S1-S86.

428

21.4

74

Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Annals of Surgery. 1983; 198: 356-69.

428

11.6

75

Deceased-donor characteristics and the survival benefit of kidney transplantation. Jama-Journal of the American Medical Association. 2005; 294: 2726-33.

425

28.3

76

Racial disparities in access to renal transplantation – Clinically appropriate or due to underuse or overuse? New England Journal of Medicine. 2000; 343: 1537-U8.

417

20.9

77

Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999; 29: 257-63.

416

19.8

78

Rabbit antithymocyte globulin versus basiliximab in renal transplantation. New England Journal of Medicine. 2006; 355: 1967-77.

414

29.6

79

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999; 68: 261-6.

410

19.5

80

Effect of waiting time on renal transplant outcome. Kidney International. 2000; 58: 1311-7.

406

20.3

81

Cyclosporine: five years’ experience in cadaveric renal transplantation. New England Journal of Medicine. 1984; 310: 148-54.

405

11.3

82

Messenger RNA for FOXP3 in the urine of renal-allograft recipients. New England Journal of Medicine. 2005; 353: 2342-51.

402

26.8

83

Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation. 1995; 59: 962-8.

399

16

84

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87: 233-42.

397

36.1

85

In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. Journal of Immunology. 1990; 144: 4604-12.

393

13.1

86

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989; 47: 606-8.

393

12.7

87

Capillary deposition of C4d complement fragment and early renal graft loss. Kidney International. 1993; 43: 1333-8.

391

14.5

88

Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation. 1999; 67: 103-9.

390

18.6

89

Expanded criteria donors for kidney transplantation. American Journal of Transplantation. 2003; 3: 114-25.

383

22.5

90

The impact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation. 2002; 73: 70-4.

378

21

91

Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. American Journal of Transplantation. 2011; 11: 2093-109.

377

41.9

92

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001; 72: 777-86.

377

19.8

93

Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. Journal of the American Society of Nephrology. 1999; 10: 2208-14.

375

17.9

94

Explained and unexplained ischemic heart disease risk after renal transplantation. Journal of the American Society of Nephrology. 2000; 11: 1735-43.

374

18.7

95

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology. 2006; 17: 581-9.

371

26.5

96

Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. Journal of the American Society of Nephrology. 2002; 13.

370

20.6

97

Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. New England Journal of Medicine. 2000; 342: 1309-15.

366

18.3

98

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation. 1999; 67: 276-84.

366

17.4

99

Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. Journal of Clinical Investigation. 2010; 120: 1848-61.

363

36.3

100

Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. Journal of the American Society of Nephrology. 2007; 18: 1046-56.

363

27.9